Roche, a leading pharmaceutical firm, declared the United States Food and Drug Administration (US FDA) has sanctioned the Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related...
Genexine, a publicly traded clinical-stage Korean biopharmaceutical company dedicated to the discovery and development of novel biologics for the treatment of serious unmet medical needs, has announced a merger with EPD Biotherapeutics (EPD Bio)...
Pulsus Group intends to establish an AI-based pharma healthcare IT cluster in Ameenpur, Sangareddy district, Telangana, at a cost of Rs 300 crore with the potential to create approximately 50,000 jobs. Pulsus Group CEO and...
Quest Diagnostics, a medical laboratories firm, reported an agreement with OMERS to buy LifeLabs, a provider of community laboratory tests for a huge number of Canadians, for a worth of around CAN $1.35 billion (around USD $985 million), including...
AstraZeneca India Private Limited (AZIPL), the British-Swedish drugmaker's global capabilities center (GCC), has announced a Rs 250 crore ($30 million) investment to expand its Global Innovation and Technology center (GITC) in...
Ipsen, a worldwide biopharmaceutical firm with an emphasis on getting groundbreaking medicines to patients in three remedial regions: oncology, interesting sickness and neuroscience, has reported confirmation of an extended partnership and license...
Bone Health Technologies (BHT), a leading medtech innovator developing breakthrough noninvasive and drug-free solutions for low bone density, announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared...
Sanofi and Regeneron received European Union permission for the expanded use of their Dupixent injection in patients with chronic lung disease, a rare instance of the EU clearing a medicine faster than the United States. The EU Commission...
Sobi declared the commencement of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212. The pivotal studies DISSOLVE I and II served as the foundation for the submission. For the treatment of...
Kedrion Biopharma Inc., a biopharmaceutical firm, declared that it has established the framework for a long-term partnership with Biotest AG for the complete commercialization and marketing of the immunoglobulin therapy Yimmugo in the United...
, CDSCO.jpg)
.jpg)